{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:11:04Z","timestamp":1793106664569,"version":"4.5.0"},"reference-count":80,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-17-RHUS-0003"],"award-info":[{"award-number":["ANR-17-RHUS-0003"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["EU H2020-847939-IP-cure-B"],"award-info":[{"award-number":["EU H2020-847939-IP-cure-B"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.cgh.2023.02.032","type":"journal-article","created":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T20:46:17Z","timestamp":1681850777000},"page":"2040-2050","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"title":["New Perspectives on Development of Curative Strategies for Chronic Hepatitis B"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2640-2211","authenticated-orcid":false,"given":"Jordan J.","family":"Feld","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5811-6845","authenticated-orcid":false,"given":"Anna S.","family":"Lok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Zoulim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2023.02.032_bib1","series-title":"Hepatitis B Fact Sheet","author":"World Health Organization","year":"2021"},{"key":"10.1016\/j.cgh.2023.02.032_bib2","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1016\/j.cgh.2020.04.091","article-title":"Should treatment indications for chronic hepatitis B be expanded?","volume":"19","author":"Jeng","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.02.032_bib3","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1053\/j.gastro.2021.11.002","article-title":"Off-therapy response after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B: an international, multicenter, multiethnic cohort (RETRACT-B study)","volume":"162","author":"Hirode","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.02.032_bib4","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.jhep.2022.01.007","article-title":"Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels","volume":"76","author":"Sonneveld","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.02.032_bib5","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1002\/hep.28144","article-title":"Liver capsule: Validated and potential novel targets to treat hepatitis B virus","volume":"62","author":"Testoni","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.02.032_bib6","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/s41573-019-0037-0","article-title":"Therapeutic strategies for hepatitis B virus infection: towards a cure","volume":"18","author":"Fanning","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.cgh.2023.02.032_bib7","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.jhep.2021.05.013","article-title":"Covalently closed circular DNA: the ultimate therapeutic target for curing HBV infections","volume":"75","author":"Martinez","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.02.032_bib8","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1053\/j.gastro.2004.03.018","article-title":"Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy","volume":"126","author":"Werle-Lapostolle","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.02.032_bib9","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.jhep.2016.05.014","article-title":"Decay of ccc-DNA marks persistence of intrahepatic viral DNA synthesis under tenofovir in HIV-HBV co-infected patients","volume":"65","author":"Boyd","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.02.032_bib10","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.cgh.2013.01.026","article-title":"Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency","volume":"11","author":"Wong","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.02.032_bib11","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1053\/j.gastro.2021.12.286","article-title":"Inhibition of viral replication reduces transcriptionally active distinct hepatitis B virus integrations with implications on host gene dysregulation","volume":"162","author":"Hsu","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.02.032_bib12","doi-asserted-by":"crossref","first-page":"e801","DOI":"10.1093\/cid\/ciac383","article-title":"Effect of antiviral treatment on hepatitis B virus integration and hepatocyte clonal expansion","volume":"76","author":"Chow","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cgh.2023.02.032_bib13","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan0241","article-title":"RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg","volume":"9","author":"Wooddell","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.cgh.2023.02.032_bib14","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02221-17","article-title":"Relative abundance of integrant-derived viral RNAs in infected tissues harvested from chronic hepatitis B virus carriers","volume":"92","author":"Freitas","year":"2018","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.cgh.2023.02.032_bib15","article-title":"Genomic and oncogenic preference of HBV integration in hepatocellular carcinoma","volume":"7","author":"Zhao","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.cgh.2023.02.032_bib16","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.jhep.2021.04.051","article-title":"Ubiquitous expression of HBsAg from integrated HBV DNA in patients with low viral load","volume":"75","author":"Meier","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.02.032_bib17","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.3390\/v14122654","article-title":"Gene editing technologies to target HBV cccDNA","volume":"14","author":"Martinez","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.cgh.2023.02.032_bib18","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41575-019-0196-9","article-title":"Restoring, releasing or replacing adaptive immunity in chronic hepatitis B","volume":"16","author":"Maini","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.02.032_bib19","doi-asserted-by":"crossref","first-page":"S851","DOI":"10.1016\/S0168-8278(22)01999-7","article-title":"Reduction of hepatitis B surface antigen mediated by RNA interference therapeutic AB-729 in chronic hepatitis B patients is associated with T cell activation and a decline in exhausted CD8 T cells","volume":"77","author":"Ganchua","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.02.032_bib20","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jhep.2017.05.008","article-title":"Hepatitis B cure: from discovery to regulatory approval","volume":"67","author":"Lok","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.02.032_bib21","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jhep.2019.11.003","article-title":"Guidance for design and endpoints of clinical trials in chronic hepatitis B - report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference","volume":"72","author":"Cornberg","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.02.032_bib22","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jhep.2018.10.014","article-title":"HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues","volume":"70","author":"Yip","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.02.032_bib23","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrgastro.2013.216","article-title":"Management of patients with hepatitis B who require immunosuppressive therapy","volume":"11","author":"Hwang","year":"2014","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.02.032_bib24","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S2468-1253(19)30119-0","article-title":"A\u00a0global scientific strategy to cure hepatitis B","volume":"4","author":"Revill","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.02.032_bib25","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1056\/NEJMra2211764","article-title":"New approaches to chronic hepatitis B","volume":"388","author":"Dusheiko","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2023.02.032_bib26","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/s41575-022-00724-5","article-title":"The scientific basis of combination therapy for chronic hepatitis B functional cure","volume":"20","author":"Lim","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.02.032_bib27","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jhep.2021.11.024","article-title":"How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development?","volume":"76","author":"Wong","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.02.032_bib28","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1053\/j.gastro.2014.04.030","article-title":"Strategies to inhibit entry of HBV and HDV into hepatocytes","volume":"147","author":"Urban","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.02.032_bib29","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1473-3099(22)00318-8","article-title":"Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial","volume":"23","author":"Wedemeyer","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cgh.2023.02.032_bib30","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20200840","article-title":"Potent human broadly neutralizing antibodies to hepatitis B virus from natural controllers","volume":"217","author":"Hehle","year":"2020","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.cgh.2023.02.032_bib31","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41586-020-2838-z","article-title":"Fc-optimized antibodies elicit CD8 immunity to viral respiratory infection","volume":"588","author":"Bournazos","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.cgh.2023.02.032_bib32","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.3390\/v13061169","article-title":"Novel antivirals in clinical development for chronic hepatitis B infection","volume":"13","author":"Mak","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.cgh.2023.02.032_bib33","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/S0168-8278(22)00437-8","article-title":"Efficacy and safety of finite 48-week treatment with the siRNA JNJ-3989 and the capsid assembly modulator (CAM-N) JNJ-6379 in HBeAg negative virologically suppressed (VS) chronic hepatitis B (CHB) patients: results from REEF-2 study","volume":"77","author":"Agarwal","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.02.032_bib34","first-page":"S18","article-title":"Safety, tolerability, and antiviral activity of the siRNA VIR-2218 in combination with the investigational neutralizing monoclonal antibody VIR-3434 for the treatment of chronic hepatitis B virus infection: preliminary results from the phase 2 MARCH trial","volume":"76","author":"Gane","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.02.032_bib35","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.jhep.2022.07.010","article-title":"Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHB","volume":"77","author":"Yuen","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.02.032_bib36","first-page":"S19","article-title":"Preliminary 48-week safety and efficacy data of VIR-2218 alone and in combination with pegylated interferon alfa in participants with chronic HBV infection","volume":"76","author":"Yuen","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.02.032_bib37","first-page":"LB5035","article-title":"Efficacy and safety of siRNA JNJ-73763989, capsid assembly modulator JNJ-56136379, nucleos(t)ide analog (NA), and pegylated interferon alpha-2a (PEGIFN\u03b12a) for treatment of chronic hepatitis B (CHB): week 24 results from the phase 2 PENGUIN study","volume":"76","author":"Gane","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.02.032_bib38","first-page":"LB5064","article-title":"Evaluation of the Vebicorvir, NRTI and AB-729 combination in virologically suppressed patients with HBeAg negative chronic hepatitis B virus infection: interim analysis from an open label phase 2 study","volume":"76","author":"George","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.02.032_bib39","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/hep.31008","article-title":"RNA interference therapy with ARC-520 results in prolonged hepatitis B surface antigen response in patients with chronic hepatitis B infection","volume":"72","author":"Yuen","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.02.032_bib40","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1136\/gutjnl-2020-323445","article-title":"Long-term serological, virological and histological responses to RNA inhibition by ARC-520 in Chinese chronic hepatitis B patients on entecavir treatment","volume":"71","author":"Yuen","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2023.02.032_bib41","first-page":"LB5047","article-title":"Hepatitis B viral control maintained during extended follow up of HBeAg- chronic hepatitis B (CHB) subjects who discontinued nucleos(t)ide analogue (NA) therapy after completion of AB-729 treatment, and in HBeAg+ subjects still on NA therapy","volume":"76","author":"Yuen","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.02.032_bib42","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jhep.2022.02.020","article-title":"Immunological biomarker discovery in cure regimens for chronic hepatitis B virus infection","volume":"77","author":"Gehring","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.02.032_bib43","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1056\/NEJMoa2210027","article-title":"Efficacy and safety of bepirovirsen in chronic hepatitis B infection","volume":"387","author":"Yuen","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2023.02.032_bib44","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.jhep.2022.05.031","article-title":"Phase IIa, randomised, double-blind study of GSK3389404 in patients with chronic hepatitis B on stable nucleos(t)ide therapy","volume":"77","author":"Yuen","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.02.032_bib45","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1038\/s41591-021-01513-4","article-title":"Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial","volume":"27","author":"Yuen","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.cgh.2023.02.032_bib46","doi-asserted-by":"crossref","first-page":"S873","DOI":"10.1016\/S0168-8278(22)02041-4","article-title":"Bepirovirsen, antisense oligonucleotide (ASO) against hepatitis B virus (HBV), harbors intrinsic immunostimulatory activity via Toll-like receptor 8 (TLR8) preclinically, correlating with clinical efficacy from the Phase 2a study","volume":"77","author":"You","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.02.032_bib47","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/s41575-022-00700-z","article-title":"Nomenclature of HBV core protein-targeting antivirals","volume":"19","author":"Zoulim","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.02.032_bib48","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1053\/j.gastro.2020.04.036","article-title":"JNJ-56136379, an HBV capsid assembly modulator, is well-tolerated and has antiviral activity in a phase 1 study of patients with chronic infection","volume":"159","author":"Zoulim","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.02.032_bib49","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S2468-1253(21)00176-X","article-title":"Safety, pharmacokinetics, and antiviral activity of RO7049389, a core protein allosteric modulator, in patients with chronic hepatitis B virus infection: a multicentre, randomised, placebo-controlled, phase 1 trial","volume":"6","author":"Yuen","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.02.032_bib50","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S2468-1253(19)30346-2","article-title":"Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial","volume":"5","author":"Yuen","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.02.032_bib51","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/cid\/ciaa961","article-title":"Antiviral activity and pharmacokinetics of the hepatitis B virus (HBV) capsid assembly modulator GLS4 in patients with chronic HBV infection","volume":"73","author":"Zhang","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cgh.2023.02.032_bib52","doi-asserted-by":"crossref","DOI":"10.1177\/13596535221127848","article-title":"EDP-514 in healthy subjects and nucleos(t)ide reverse transcriptase inhibitor-suppressed patients with chronic hepatitis B","volume":"27","author":"Feld","year":"2022","journal-title":"Antivir Ther"},{"key":"10.1016\/j.cgh.2023.02.032_bib53","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jhep.2022.04.005","article-title":"Safety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infection","volume":"77","author":"Yuen","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.02.032_bib54","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jhep.2022.05.027","article-title":"Safety and efficacy of vebicorvir administered with entecavir in treatment-naive patients with chronic hepatitis B virus infection","volume":"77","author":"Sulkowski","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.02.032_bib55","first-page":"S736","article-title":"Viral response and safety following discontinuation of treatment with the core inhibitor vebicorvir and a nucleos (t)ide reverse transcriptase inhibitor in patients with HBeAg positive or negative chronic hepatitis B virus infection","volume":"75","author":"Gane","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.02.032_bib56","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1002\/hep4.2095","article-title":"Safety, pharmacokinetics, and antiviral activity of the capsid inhibitor AB-506 from Phase 1 studies in healthy subjects and those with hepatitis B","volume":"6","author":"Yuen","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.cgh.2023.02.032_bib57","doi-asserted-by":"crossref","first-page":"S864","DOI":"10.1016\/S0168-8278(22)02024-4","article-title":"Effects of the siRNA JNJ-3989 and\/or the capsid assembly modulator (CAM-N) JNJ-6379 on viral markers of chronic hepatitis B (CHB): results from the REEF-1 study","volume":"77","author":"Yuen","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.02.032_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104853","article-title":"Characterization of the antiviral effects of REP 2139 on the HBV lifecycle in\u00a0vitro","volume":"183","author":"Boulon","year":"2020","journal-title":"Antiviral Res"},{"key":"10.1016\/j.cgh.2023.02.032_bib59","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1053\/j.gastro.2020.02.058","article-title":"Safety and efficacy of 48 weeks REP 2139 or REP 2165, tenofovir disoproxil, and pegylated interferon alfa-2a in patients with chronic HBV infection naive to nucleos(t)ide therapy","volume":"158","author":"Bazinet","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.02.032_bib60","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1053\/j.gastro.2013.02.003","article-title":"GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees","volume":"144","author":"Lanford","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.02.032_bib61","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jhep.2017.10.027","article-title":"Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B","volume":"68","author":"Janssen","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.02.032_bib62","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/hep.31695","article-title":"Therapeutic potential of TLR8 agonist GS-9688 (Selgantolimod) in chronic hepatitis B: remodeling of antiviral and regulatory mediators","volume":"74","author":"Amin","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.02.032_bib63","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1002\/hep.31795","article-title":"Safety, pharmacokinetics, and pharmacodynamics of the oral TLR8 agonist selgantolimod in chronic hepatitis B","volume":"74","author":"Gane","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.02.032_bib64","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/liv.15465","article-title":"A\u00a0phase 2, open-label, randomized, multiple-dose study evaluating Inarigivir in treatment-naive patients with chronic hepatitis B","volume":"43","author":"Yuen","year":"2023","journal-title":"Liver Int"},{"key":"10.1016\/j.cgh.2023.02.032_bib65","first-page":"S125","article-title":"Liver toxicity in the phase 2 Catalyst 206 trial of inarigivir 400 mg daily added to a nucleoside in HBV EAg negative patients","volume":"73","author":"Agarwal","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.02.032_bib66","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.jhep.2019.06.028","article-title":"Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: A pilot study","volume":"71","author":"Gane","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.02.032_bib67","doi-asserted-by":"crossref","first-page":"S868","DOI":"10.1016\/S0168-8278(22)02030-X","article-title":"Phase 1b\/2a study of heterologous ChAdOx1-HBV\/MVA-HBV therapeutic vaccination (VTP-300) combined with low-dose nivolumab (LDN) in virally-suppressed patients with CHB on nucleos (t)ide analogues","volume":"77","author":"Evans","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.02.032_bib68","doi-asserted-by":"crossref","first-page":"470","DOI":"10.3390\/biom12030470","article-title":"PD-L1 silencing in liver using siRNAs enhances efficacy of therapeutic vaccination for chronic hepatitis B","volume":"12","author":"Bunse","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.cgh.2023.02.032_bib69","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1016\/S0168-8278(22)00538-4","article-title":"ALT flares were linked to HBsAg reduction, seroclearance and seroconversion: interim results from a phase IIb study in chronic hepatitis B patients with 24-week treatment of subcutaneous PD-L1 Ab ASC22 (Envafolimab) plus nucleos (t)ide analogs","volume":"77","author":"Wang","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.02.032_bib70","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1053\/j.gastro.2018.10.032","article-title":"Targeting innate and adaptive immune responses to cure chronic HBV infection","volume":"156","author":"Gehring","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.02.032_bib71","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.coviro.2021.10.002","article-title":"Immunotherapy and therapeutic vaccines for chronic HBV infection","volume":"51","author":"Lang-Meli","year":"2021","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.cgh.2023.02.032_bib72","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1053\/j.gastro.2020.01.032","article-title":"Knockdown of virus antigen expression increases therapeutic vaccine efficacy in high-titer hepatitis B virus carrier mice","volume":"158","author":"Michler","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.02.032_bib73","doi-asserted-by":"crossref","first-page":"S831","DOI":"10.1016\/S0168-8278(22)01959-6","article-title":"Dose-dependent durability of hepatitis B surface antigen reductions following administration of a single dose of VIR-3434, a novel neutralizing vaccinal monoclonal antibody","volume":"77","author":"Agarwal","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.02.032_bib74","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.jhep.2022.06.010","article-title":"Bulevirtide with or without pegIFNalpha for patients with compensated chronic hepatitis delta: from clinical trials to real-world studies","volume":"77","author":"Lampertico","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.02.032_bib75","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jhep.2022.03.006","article-title":"A\u00a0case of HBV-induced liver failure in the REEF-2 phase II trial: Implications for finite treatment strategies in HBV 'cure'","volume":"77","author":"Agarwal","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.02.032_bib76","first-page":"LB5012","article-title":"Efficacy and safety of combination treatment with siRNA JNJ-73763989 and capsid assembly modulator JNJ-56136379 (Bersacapavir) in HBeAg negative virologically suppressed chronic hepatitis B (CHB) patients: follow-up week 48 end of study results from REEF-2","volume":"76","author":"Agarwal","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.02.032_bib77","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41575-022-00649-z","article-title":"A\u00a0roadmap for serum biomarkers for hepatitis B virus: current status and future outlook","volume":"19","author":"Kramvis","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.02.032_bib78","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/hep.26041","article-title":"Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads","volume":"57","author":"Tseng","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.02.032_bib79","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.jhep.2018.11.030","article-title":"Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients","volume":"70","author":"Testoni","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.02.032_bib80","article-title":"Assessing immunological and virological responses in the liver: Implications for the cure of chronic hepatitis B virus infection","volume":"4","author":"Boettler","year":"2022","journal-title":"JHEP Rep"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356523002793?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356523002793?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:43:23Z","timestamp":1761543803000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356523002793"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":80,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S1542356523002793"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2023.02.032","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New Perspectives on Development of Curative Strategies for Chronic Hepatitis B","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2023.02.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the AGA Institute","name":"copyright","label":"Copyright"}]}}